Phase 2 × Recruiting × Squamous Cell Carcinoma of Head and Neck × Clear all Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
Phase 2 Recruiting
38 enrolled
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
188 enrolled
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Phase 2 Recruiting
150 enrolled
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
Phase 2 Recruiting
30 enrolled
KIEO
Phase 2 Recruiting
30 enrolled
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Phase 2 Recruiting
27 enrolled
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Phase 2 Recruiting
189 enrolled
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Phase 2 Recruiting
29 enrolled
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Phase 2 Recruiting
25 enrolled
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
Phase 2 Recruiting
21 enrolled
3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial
Phase 2 Recruiting
108 enrolled
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
Phase 2 Recruiting
40 enrolled
Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma
Phase 2 Recruiting
250 enrolled
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2 Recruiting
66 enrolled
REDUCE
Phase 2 Recruiting
86 enrolled
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Phase 2 Recruiting
28 enrolled
LIFTING2
Phase 2 Recruiting
60 enrolled
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 Recruiting
492 enrolled
HN001
Phase 2 Recruiting
90 enrolled
A Study of Radiation Therapy After Surgery in People With Oral Tongue Squamous Cell Carcinoma
Phase 2 Recruiting
24 enrolled
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
Phase 2 Recruiting
150 enrolled
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Phase 2 Recruiting
98 enrolled
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Phase 2 Recruiting
32 enrolled
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma
Phase 2 Recruiting
70 enrolled
A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
60 enrolled
Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer
Phase 2 Recruiting
70 enrolled
Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
81 enrolled
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Phase 2 Recruiting
50 enrolled
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Phase 2 Recruiting
225 enrolled
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
Phase 2 Recruiting
30 enrolled
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Phase 2 Recruiting
50 enrolled
A Study of YL202 in Selected Patients With Advanced Solid Tumors
Phase 2 Recruiting
200 enrolled
SAVAL
Phase 2 Recruiting
61 enrolled
Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma
Phase 2 Recruiting
40 enrolled
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
Phase 2 Recruiting
43 enrolled
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Phase 2 Recruiting
186 enrolled
SURVEILLE-HPV
Phase 2 Recruiting
420 enrolled
ERBIOTAX
Phase 2 Recruiting
65 enrolled
Pembrolizumab in Combination With Low-dose PFas Neoadjuvant Treatment for Locally Advanced HNSCC
Phase 2 Recruiting
80 enrolled
Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial
Phase 2 Recruiting
50 enrolled
Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC
Phase 2 Recruiting
39 enrolled
Iparomlimab and Tuvonralimab in HNSCC
Phase 2 Recruiting
30 enrolled
Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negative, Anti-PD-1-resistant R/M HNSCC
Phase 2 Recruiting
98 enrolled
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck
Phase 2 Recruiting
116 enrolled
Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC
Phase 2 Recruiting
86 enrolled
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Phase 2 Recruiting
28 enrolled
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Phase 2 Recruiting
245 enrolled
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial)
Phase 2 Recruiting
83 enrolled
AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy
Phase 2 Recruiting
52 enrolled
FAPIHN
Phase 2 Recruiting
20 enrolled